07.09.2017 • NewsDede WillamsleadershipNovartis

Jimenez to Quit Novartis Next Year

Novartis CEO Joseph Jimenez has announced he will leave the Swiss-based...
Novartis CEO Joseph Jimenez has announced he will leave the Swiss-based drugnaker in early 2018, after eight years at the helm, and return to his native US

Novartis CEO Joseph Jimenez has announced he will leave the Swiss-based drugnaker in early 2018, after eight years at the helm, and return to his native US. However, he will remain "available for advice and support" until his official retirement on Aug. 31, Novartis said in a statement.

Jimenez will be succeeded in Basel by another American,Vasant Narasimhan, at present chief medical officer and global head of drug development. Narasimhan joined Novartis in 2005 and has held a variety of leadership positions.

The current Novartis chief focused the drugmaker on leading global businesses, while divesting non-core divisions, supervisory board chairman Joerg Reinhardt said. "Under his leadership the innovation pipeline was rejuvenated, and we successfully navigated the patent expirations of our two largest products."

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.